Twenty years of global expertise in Nervous System Disorders

The global burden of neurological disorders, including all diseases of the brain, cranial nerves, spinal cord, peripheral nerves, and neuromuscular systems, is increasing and becoming highly prevalent, especially in low-resource parts of the world. At least one in three people will have a neurological disease sometime during their lifetime. Between 1990 and 2016, neurological disorders were the leading cause of disability-adjusted life years (DALYs)—the second most significant cause of death globally, accounting for nine million deaths yearly. The current increased international interest in brain health and its impact on population well-being and economic growth, highlighted in the World Health Organization’s new Intersectoral Global Action Plan on Epilepsy and other Neurological Disorders 2022–2031, presents an opportunity to increase the number of nervous system clinical trials significantly.

Our dedicated team responsible for nervous system disorders is working in five directions:

• Autoimmune diseases of the nervous system
• Neurodegenerative disorders
• Epilepsy
• Neuropathy and pain
• Other conditions of the nervous system (neurotrauma, stroke, infections)

In the past two decades, Accelsiors’ Teams have witnessed tremendous progress in elucidating the causes of some nervous system disorders

Twenty years of continuous experience in autoimmune disorders of the nervous system

Autoimmune disorders of the nervous system may affect any part of the nervous system, including the brain and spinal cord (central nervous system, CNS) and the peripheral nerves, neuromuscular junction, and skeletal muscle. The central and peripheral nervous system’s autoimmune disorders may be triggered by diverse factors in genetically susceptible individuals.

In the past two decades, Accelsiors’ Teams have witnessed tremendous progress in elucidating the causes of some nervous system disorders. At that time, we have been guessing their etiology and the most appropriate causal therapies; today, we understand, for instance, how Neuromyelitis Optica Spectrum Disorders, Myelin oligodendrocyte glycoprotein-antibody associated disease, or other encephalitis caused by antibodies to synaptic receptors in the CNS are developing, and how a rapid diagnosis and treatment could be a game changer in the outcome of these disorders.

Accelsiors experience augmented with historical understanding autoimmune disorders of nervous system is a guarantee for successful conduct of new studies in this field.

Twenty years expertise in Alzheimer, Parkinson diseases, and ALS

Neurodegenerative disorders’ underlying mechanisms and pathophysiology are often complex and not fully understood. This knowledge gap can make it challenging to identify appropriate targets for intervention and design effective treatment strategies.

Neurodegenerative disorders encompass a range of diseases with varied etiologies, disease subtypes, and clinical presentations. The heterogeneity of patient populations can make it challenging to identify and recruit eligible participants who match specific inclusion criteria, potentially affecting the generalizability of study results.

Neurodegenerative disorders are often chronic and progressive, making it challenging to measure treatment effects over a relatively short trial duration. Disease progression can mask or confound the efficacy of an intervention, leading to challenges in demonstrating treatment benefits.